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Background: The availability of multiple in silico tools for prioritizing genetic variants widens the possibilities for
converting genomic data into biological knowledge. However, in molecular cytogenetics, bioinformatic analyses
are generally limited to result visualization or database mining for finding similar cytogenetic data. Obviously, the
potential of bioinformatics might go beyond these applications. On the other hand, the requirements for
performing successful in silico analyses (i.e. deep knowledge of computer science, statistics etc.) can hinder the
implementation of bioinformatics in clinical and basic molecular cytogenetic research. Here, we propose a
bioinformatic approach to prioritization of genomic variations that is able to solve these problems.
Results: Selecting gene expression as an initial criterion, we have proposed a bioinformatic approach combining
filtering and ranking prioritization strategies, which includes analyzing metabolome and interactome data on
proteins encoded by candidate genes. To finalize the prioritization of genetic variants, genomic, epigenomic,
interactomic and metabolomic data fusion has been made. Structural abnormalities and aneuploidy revealed by
array CGH and FISH have been evaluated to test the approach through determining genotype-phenotype correlations,
which have been found similar to those of previous studies. Additionally, we have been able to prioritize copy number
variations (CNV) (i.e. differentiate between benign CNV and CNV with phenotypic outcome). Finally, the approach has
been applied to prioritize genetic variants in cases of somatic mosaicism (including tissue-specific mosaicism).
Conclusions: In order to provide for an in silico evaluation of molecular cytogenetic data, we have proposed a
bioinformatic approach to prioritization of candidate genes and CNV. While having the disadvantage of possible
unavailability of gene expression data or lack of expression variability between genes of interest, the approach
provides several advantages. These are (i) the versatility due to independence from specific databases/tools or
software, (ii) relative algorithm simplicity (possibility to avoid sophisticated computational/statistical methodology) and
(iii) applicability to molecular cytogenetic data because of the chromosome-centric nature. In conclusion, the approach
is able to become useful for increasing the yield of molecular cytogenetic techniques.
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To produce biological knowledge on the basis of high-
throughput analyses of genome, in silico methods are
required. Technical resource limitations in acquiring and
validating data on mechanisms and consequences of gen-
etic variants suggest the robust selection to underlie the as-
sociations with phenotypic traits. Consequently, candidate
gene prioritization seems to represent a valuable approach
to validate genomic associations in silico and, more import-
antly, to exacerbate the significance of molecular findings
[1,2]. Actually, functional characteristics of genes seem to
be the most useful parameters for establishing genetic
associations [3-6]. However, there is a strong evidence
from molecular cytogenetic studies that copy numbers of
genes involved in a variety of critical biological processes
can be variable without apparent phenotypic effect [7,8].
Therefore, one can propose bioinformatic classification of
genetic variants to be important for distinguishing between
benign and pathogenic mutations.
Recently, several bioinformatic assays applicable to
molecular cytogenetics have been described and have
served as a basis to develop more sophisticated tech-
niques to detect chromosomal rearrangements and to
generalize genomic data [9-13]. Notwithstanding, bio-
informatic methods are rarely used in molecular cytogen-
etic studies. Our own efforts in this regard have been made
to define the consequences of genomic variations accord-
ing to in silico surveying gene expression [14-16]. Despite
this relative success, requirements of additional selection
criteria and more detailed in silico analysis of genome
(epigenome and proteome) data have been acknowledged.
Here, incorporating several new features (selection criteria)
and integration/fusion of data from multiple databases/re-
sources, we propose a bioinformatic approach to prioritiza-
tion of candidate genes and copy number variations (CNV).
We further speculate that this approach can be useful for
basic and applied molecular cytogenetic genome research.
Results and discussion
Gene expression as a criterion for the prioritization
The variability of expression profiles between genes lo-
cated in a genomic locus in a given tissue is relatively
stable. Moreover, a number of epigenetic databases (i.e.
BioGPS [17]) provide rather visualization of such variabil-
ity than gene-specific expression data. Using the same idea
as proposed earlier for tissue-specific genome pathology
(i.e. brain diseases should primarily result from genomic
alterations affecting brain tissue) [18], we have hypothe-
sized that a gene mutation (CNV/chromosome rearrange-
ment) is likely to be associated with specific trait if the
gene is expressed more abundantly in the affected tissue.
Thus, our model suggests that a genetic variant is more
likely to have a phenotypic outcome due to dysfunctions
in specific tissues or cell lineages. The latter appears to beachieved through unequal distribution of gene expression
patterns in different tissues. Hence, it becomes possible to
attribute genes involved in a chromosome rearrangement
or CNV to specific cellular processes or tissue pathology.
Gene expression has long been recognized as a valuable
criterion of classifying cellular or pathological states and
prioritizing genetic variants [19,20]. Furthermore, alter-
ations to gene expression are associated with pathological
conditions and are able to indicate changes in molecular
pathways [21]. Therefore, gene expression may be appro-
priate as the second step in filtering strategy, following the
first (empirical) filter of detecting genomic variations
(molecular cytogenetic analysis of chromosome abnormal-
ities or CNV) highlighting genes, which are to be analyzed
bioinformatically. Nevertheless, to increase the efficiency
of gene prioritization additional filters and ranking strat-
egies are needed.
From genes to pathways and back again
Filtering strategy based on analysis of genomic/epigenomic
databases has been combined with a ranking strategy and
other properties of selected genes (proteins), acquired from
complementary data sources, have been considered to
define the most promising candidates. The definitions of
filtering and ranking strategies for data fusion have been
previously described in Moreau and Tranchevent, 2012 [1].
Following gene selection according to their expression
profiles, additional data was acquired from proteomic
databases (i.e. consequences of gene mutations at protein
level, interactions between proteins (interactome networks),
pathways (“reactome”) and metabolic processes or metabo-
lome). Moreover, genetic variants were addressed in Data-
base of Genomic Variants (http://dgvbeta.tcag.ca). Using
these data to associate genetic variability with phenotypic
traits, it has become possible to identify candidate processes
for a disease in addition to candidate genes. An outline of
the procedure is given in Figure 1.
Specific interactomes and metabolomes can be used for
prioritization of genes outside of chromosome imbalance
or CNV. The scheme of such prioritization would look as
follows: (i) genes involved in a genomic rearrangement (or
mutated genes) are selected according to the gene expres-
sion profiles; (ii) data acquired from genomic/proteomic/
metabolomic are used to construct the network or path-
way specific for a clinical condition or phenotypic trait;
(iii) other elements (genes) of this network/pathway are
evaluated by the approach. Therefore, the applications of
the approach are not limited to those genes involved in a
chromosome imbalance or CNV.
Integrating multiple data sources is likely to be the most
appropriate way to prioritizing genes using in silico tech-
niques [22]. This can be done through the evaluation of
ontology-based gene similarities [2], fusion of data from
different resources [3], or analyzing of protein interaction
Figure 1 Outline of the basic procedure: molecular cytogenetic data (i.e. genes involved in a chromosome imbalance) is analyzed
using epigenetic (gene expression) databases. According to epigenetic in silico analysis candidate genes are initially prioritized. Nextly,
interactome analysis of proteins encoded by candidate genes is done. All these data is then fused for identification of disease candidate processes.
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informatic analyses can be confirmed by a “clinical verifica-
tion” or in other words, genotype-phenotype correlations.
However, such verification has a disadvantage inasmuch as
phenotypic outcomes can be intricate or can manifest later
in life. Genetic variants causing susceptibility to complex
diseases represent another problem regardless of the wide-
spread ignorance in terms of CNV pathogenic value. Here,
one has to consider the fact that this genetic problem has
not as yet been solved in a satisfactory manner.
Gene prioritization in chromosomal imbalances
Structural chromosomal imbalances and aneuploidy have
been used as a model for gene prioritization because of
recognizable phenotypes (ease of correlation between
genotypes and phenotypes) and positive data on molecular
definition of chromosomal syndromes. Taking the most
prominent example of chromosomal imbalances referred
to as trisomy of chromosome 21 or Down’s syndrome, we
have tested the approach by analysis of candidate genes
for brain malfunction in this devastating disease. Firstly,
the alignment of gene expression profiles within fetal and
adult brain tissues was made (Figure 2). The selected
genes (outliers) (CXADR, GABPA, APP, TIAM1, SYNJ1,
SON, ATP5O, TTC3, HMGN1, PDXK, SUMO3, S100B)
were further evaluated using the ranking strategy. Com-
paring these data with those on brain dysfunction
pathways in Down’s syndrome [23], we have found that
disease networks matched the networks of the present
study. Trisomy 21 provides an example how karyotype
alterations achieve a broad impact on (cellular) phenotype,affecting simultaneously many genes and changing the
expression of genes outside of chromosome 21 [18,23].
Accordingly, this is achieved through alterations to several
pathways, among which are chromatin remodeling and
gene expression regulation. Apparently, the way these
pathways are altered is likely to be properly evaluated by
in silico molecular cytogenetic approaches. Although these
results were generally expected, one can agree that this
testing shows the applicability of the bioinformatic
approach. We also have performed bioinformatic analysis
of two cases of terminal 7q loss detected by array compara-
tive genomic hybridization (CGH). The first case was an
unbalanced translocation t(7q;21q)(q34;q22.13) reported
previously [24], whereas the second one was a deletion of
7q36. Both cases were featured by characteristic facial
dysmorphisms, intellectual disability, and lumbosacral
dysgenesis. Using array CGH and fluorescence in situ
hybridization (FISH), we have narrowed the region of
chromosome 7 (7q36.2q36.3 spanning from ~152 Mb
to ~158 Mb) associated with common phenotypic features
in these two cases. Using the present bioinformatic ap-
proach, LIMBR1 and MNX1 have been prioritized as can-
didates for lubosacral dysgenesis out of 45 genes located
within the chromosome 7q36.2q36.3 region. Previously, we
have confirmed candidate genes involved in chromosome
abnormalities within a set of individuals suffering from
intellectual disability, autism, epilepsy and/or congenital
anomalies. The gene list has been provided in our previous
studies [15,16]. In addition to previous data, candidate
processes for these conditions were proposed: DNA repli-
cation, DNA damage and repair, nucleotide excision/
Figure 2 Alignment of gene expression profiles in the fetal/whole brain and prefrontal cortex to chromosome 21 long arm. Each
expression profile (ordinates) was placed on the graph according to gene localization (abscissa) acquired from NCBI Map Viewer. Gene expression
profiles were acquired from www.biogps.org [17].
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way, p53-/MAPK-/ErbB-/PI3KAkt-signaling, G1 to S cell
cycle control, MAPK signaling pathway, mitotic cell cycle
G1/S transition DNA damage checkpoint, p53-Dependent
G1 DNA damage response and V(D)J recombination, axon
guidance. Interestingly, an analysis of genome-wide associ-
ations studies in the light of somatic genomics of brain dis-
eases has shown genes implicated in these pathways to be
involved in the pathogenesis, as well [12]. Taken together,
the approach seems to provide a possibility for prioritizing
not only candidate genes according to (molecular) cytogen-
etic data but also alterations to molecular/cellular pathways
and, thereby, candidates processes.
Naturally, the first filter in a molecular cytogenetic
analysis is the chromosome abnormality or CNV itself,
inasmuch as it narrows the search of candidates to a
chromosomal region or even to a single gene. Computa-
tional genome annotation in cytogenetic analysis provides a
possibility of associations between genes and manifestations
of chromosomal imbalances [25]. However, such associa-
tions require additional molecular cytogenetic studies in
larger cohorts or further molecular analyses of suggested
candidate genes. The apparent lack of success in mapping
genes of complex diseases (regardless of data on myriads of
genetic variants associated with) evidences that, rather than
gene hunting, specific changes in molecular/cellular pro-
cesses should be considered as targets for the research and
therapeutic interventions. In acknowledging this issue, an
opportunity for uncovering disease pathways on the basisof molecular cytogenetic data is likely to be an important
technological milestone.
Another implication of in silico molecular cytogenetics is
the identification of regional genomic architecture leading
to susceptibility to the formation of genome/chromosome
rearrangements [26,27]. The capability of the present
approach to acquire such data [15,24] would be useful for
molecular cytogenetic research and diagnosis allowing the
prediction of germline and somatic chromosomal/genomic
rearrangements [28]. Thus, in silico molecular cytogenetics
of chromosome imbalances should include the analysis of
genomic databases for identification of regional genomic
architecture in addition to gene prioritization.CNV prioritization
The determination of CNV pathogenicity can be designated
as CNV prioritization. A phenotypic outcome has been
proposed as the main criterion for CNV prioritization. To
identify potential phenotypic effects of CNV by the present
approach, the presence of at least one prioritized gene has
been considered a criterion for the prioritization. The distri-
bution of prioritized CNV detected by array CGH in the
cohort (n = 205) is shown in Figure 3. In total, 462 CNV
were prioritized in 181 patients giving a potential diagnostic
yield of as high as 88.3%. It is to note that the distribution
remotely resembles the normal (or Gaussian) distribution.
This has allowed us to speculate that amount of causative
CNV per patient has a tendency to vary generally between
Figure 3 CNV prioritization (abscissa: amount of CNV prioritized
in each individual; ordinates: numbers of patients with the
corresponding amount of CNV prioritized). CNV detection was
made by array CGH.
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mental (brain) diseases (Figure 3).
The problem of differentiating between pathogenic and
benign CNV seems to remain actual [7,8,16,25]. Further-
more, better understanding of genetic variation and its
relevance to mechanisms of neurodevelopmental diseases
has been originated from application of high-throughput
genome analyses [29]. Although there has been described
several ways to process the data for identification of
disease mechanisms [8,29], interpretation of a patient’s
variome represents a challenge. Indeed the success of such
analysis can give valuable information for understanding
disease mechanisms and, as a result, suggest therapeutic
interventions. Furthermore, CNV prioritization in larger
cohorts might indicate as candidate disease processes as
molecular and cellular pathways implicated in complex
biological phenomena (i.e. aging, cell cycle control, tran-
scriptional regulation, chromatin remodeling, genome
stability maintenance) [12,30-32].
In silico molecular cytogenetic analysis of somatic
mosaicism
To test the possibility of developing an in silico molecular
cytogenetic method for evaluating somatic genome varia-
tions (SGV), we have processed the data on interphase
and metaphase FISH analysis of about 5000000 cells from
150 samples. SGV were analyzed in two ways: (i) evalu-
ation of SGV consequences in terms of cellular or clinical
phenotype [14]; (ii) analysis of variome (non-mosaic varia-
tions in an individual genome) to hypothesize SGV origins
[12]. The former way was mainly used for structural gen-
omic variations and genomic instability (GIN) while the
latter way was used for analyzing origins of chromosome
instability (CIN) or aneuploidy/polyploidy [12,33]. In the
set of samples analyzed by FISH-based techniques, aneu-
ploidy has been the most common type of mosaic genome
variations. Since aneuploidy represents one of the mostdevastating types of SGV, affecting from hundreds to
thousands genes and impacting on cellular phenotype
[34,35], consequences of aneuploidization were not sug-
gested to require further bioinformatic evaluations in the
phenotypic context. Moreover, the effect of chromosome
number variations has been recently modeled for asses-
sing somatic genome evolution in cancer showing elevated
tolerance to aneuploidy or, in other words, global changes
to genomic (epigenomic) landscape [36]. However, GIN
and CIN manifested as chromosome breaks and rearrange-
ments were found to be appropriate for finding genomic
loci susceptible to breakage (i.e. chromosomal fragile sites
and chromosomal regions containing highly repetitive
DNA) and mapping genes disrupted by CIN in brain
disease (ataxia-telangiectasia and Alzheimer’s disease) (for
more details see [14,37]). It is noteworthy that these
genomic changes cannot be detected by high-throughput
technologies of whole genome analysis. Therefore, such
types of GIN/CIN are rarely evaluated by an in silico ana-
lysis, even though knowledge of their effects on cellular/
clinical phenotypes is able to shed light on new genetic
mechanisms of biodiversity and disease [38]. Alternatively,
it has been shown that either SGV or non-mosaic genomic
variations can dysregulate chromosome segregation and
genomic maintenance producing CIN or GIN [12]. These
observations were used for suggesting that bioinformatic
approaches might be useful for studying mechanisms and
consequences of somatic mosaicism. Finally, the present
approach based on prioritizing genetic variants using evalu-
ation of epigenetic variation between tissues and cell types
can be utilized in studies of tissue-specific mosaicism.
Until recently, somatic mosaicism has not been a major
focus of genome research [33,39]. With the increase of
interest in addressing SGV, several studies have posed
questions about the relevance of SGV to genetic diversity
and morbidity [39-41]. It is repeatedly noted that SGV are
underrecognized sources of genomic, chromosomal and
complex disorders [18,33,39,41]. Additionally, SGV affect-
ing specific tissues often lead not only to cancer, but also
to tissue-specific pathology. For instance, numerous brain
diseases are associated with SGV (CIN/GIN) manifested as
aneuploidy or structural genome variations [14,18,37,
42-48]. These data have served as a basis for speculations
about diagnostic applications of SGV analysis in brain dis-
ease and regeneration therapy [49]. Still, the idea remains
undeveloped and further theoretical input is needed. It can
be expected that molecular cytogenetic studies of SGV
would benefit from in silico evaluations of their mecha-
nisms and consequences.
Conclusions
Bioinformatics can help in avoiding extensive laboratory
efforts, but requires deep knowledge in computer science,
statistics and related disciplines. Nevertheless, the existence
Figure 4 (See legend on next page.)
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Figure 4 In silico molecular cytogenetics (flow chart of the approach). Molecular cytogenetic data (genome data) acquired through
techniques for whole-genome scan (i.e. array CGH) and detecting SGV (i.e. interphase FISH) is analyzed by the bioinformatic approach
(genome, epigenome, interactome and metabolome or “reactome” analysis), which is able not only to define interplay between mosaicism,
CIN and GIN with heritable/de novo (non-mosaic) genomic variations, but also to identify candidate disease processes allowing appropriate
genotype-phenotype correlations and, thereby, determination of intrinsic disease mechanisms. The latter has the potential to become a basis
for successful personalized molecular therapy (scheme was partially inspired by [10,28,52]).
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plify the use of bioinformatics. Here, a bioinformatic ap-
proach to prioritization of candidate genes and CNV
based on analysis of genomic/epigenetic/proteomic and
metabolomic databases/online tools has been proposed.
According to our evaluations, it seems that the approach
possesses simplicity inasmuch as it does not require so-
phisticated computational or statistical methodology.
Another advantage of the present bioinformatic approach
is the versatility or, more precisely, the independence from
the use of specific software and databases (online tools).
Combining molecular cytogenetic resolution in whole-
genome scanning and single-cell chromosomal analysis
[50-52] with the power of bioinformatic analyses of tran-
scriptomic and proteomic data [53-55], the approach is able
to shed light on interplay between SGV and non-mosaic
chromosomal/genomic rearrangements. Further, filtering
and ranking genomic, epigenomic (gene expression), inter-
actomic (protein networks) and metabolomics (“reactome”/Table 1 Databases, tools, resources and software used in the
Database-tool-resource-software URL
UCSC Genome Browser (Version: Feb. 2009
GRCh37/hg19)
http://genome.ucsc.ed
Ensembl Genome Browser http://www.ensembl.o
NCBI Build 37.1/NCBI Map Viewer http://www.ncbi.nlm.n
cgi?taxid=9606
Database of Genomic Variants http://dgvbeta.tcag.ca
OMIM (online Mendelian inheritance in Man) http://www.omim.org
DECIPHER (Database of Chromosomal Imbalance
and Phenotype in Humans using Ensembl Resources)
http://decipher.sange
Phenotype-Genotype Integrator (PheGenI) http://www.ncbi.nlm.n




Cytoscape software (Version: 3.1.1) http://www.cytoscape
Reactome http://www.reactome
Pathway commons http://www.pathwayc
KEGG (Kyoto Encyclopedia of Genes and Genomes) http://www.genome.j
NCBI BioSystems Database http://www.ncbi.nlm.n
NCBI gene http://www.ncbi.nlm.n
PubMed http://www.ncbi.nlm.n
Google scholar http://www.scholar.gopathways) data followed by the fusion forms the basis
for prioritizing candidate disease processes. These are
certainly useful for making genotype-phenotype correla-
tions, elucidating disease mechanisms, and developing
personalized molecular therapy. Taken together, these
theoretical perspectives provide the foundation of in
silico molecular cytogenetics, basic principles (outline) of
which are schematically illustrated in Figure 4. It is to
note that this scheme is a kind of flow chart of our bio-
informatic approach, as well. To this end, one can still
conclude that further steps to make in silico molecular
cytogenetics more practical are certainly required.
Methods
Molecular cytogenetic techniques (sample preparation,
FISH and array CGH)
We have analyzed the results of array CGH of 205 patients.
Additionally, data on interphase FISH analysis of about
5000000 cells from 150 samples (metaphase and interphasepresent study
Acquired data or application











.org/ [60] Interactome analysis




ih.gov/gene/ Various gene information
ih.gov/pubmed/ Bibliographic searches and
evaluations
ogle.com/
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http://www.molecularcytogenetics.org/content/7/1/98analyses) were bioinformatically evaluated. Array CGH was
performed as described previously [16,56]. FISH analyses
of metaphase chromosomes were presented earlier [44,57].
Sample preparation for interphase FISH was made accord-
ing to a previously described protocol [58]. Results of inter-
phase and metaphase FISH with chromosome numeration,
site-specific and multicolor banding DNA probes were
described in our previous communications [14,37,42,44,
45,48,52,57].Bioinformatics
Genomic, epigenomic, proteomic and metabolomic data
was analyzed as described previously [1-6,12,14-16,59].
The data on each gene involved in chromosome abnormal-
ities and/or CNV were acquired from clinical, genomic
(browsers and gene ontology databases), epigenetic (gene
expression), proteomic, interactomic (databases + software)
and metabolomic databases. Firstly, genes were selected
according to the gene expression patterns. Proteomic and
metabolomic data were used to confirm the selection.
More precisely, epigenetic (expression) and metabolic
“tissue-specificity” was used as a criterion for the selection
(for more details see [17] and [59]). Interactomic data was
visualized and processed using Cytoscape software [60].
Metabolomic data was acquired from multiple sources
(i.e. gene ontology databases and the Reactome pathway
knowledgebase [61]).
The prioritization was made by ontology-based gene
filtering (i.e. selection of genes according to their direct
relevance to the phenotype or to their involvement in
molecular/cellular processes relevant to a trait). Afterwards,
ontology-based gene-specific ranking of gene properties
was used. To finalize the prioritization, simulating pathway
alterations (i.e. analyzing proteomic networks without
elements referred to mutated/deleted/duplicates genes) was
made and then, the selection of candidate processes for
pathology in each given case was done. The prioritization
of one or more genes in a CNV encompassing several
genes was considered as an essential criterion for the
prioritization. Information from clinical and molecular
databases was arbitrarily re-evaluated by a bibliographic
analysis assessing the level of publications (citations, com-
ments etc.) about features of interest in light of the pheno-
typic outcome.Databases and software
Databases and software used in the present study are
outlined in Table 1.
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